• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Derivation and Validation of a Proposed Long Length of Stay (>= 7 days) Score in Patients Hospitalized for Acute Ischemic Stroke (P1.067)
Conclusions:Many factors play a role in determining the length of stay for AIS patients. Our study provides a scoring system that may help physicians predict which patients are more likely to have a prolonged hospital stay.Disclosure: Dr. Mahmood has nothing to disclose. Dr. Ali has nothing to disclose. Dr. Chauhan has nothing to disclose. Dr. Bianchi has nothing to disclose. Dr. Singhal has received personal compensation for activities with Medicolegal, ACTION Trial Stroke, Biogen, and Dock Technologies. Dr. Singhal holds stock and/or stock options in Biogen. Dr. Singhal has received research support from Boehringer Ingel...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Mahmood, S., Ali, S., Chauhan, M. A., Bianchi, N., Singhal, A., Schwamm, L. Tags: Practice, Policy, and Ethics I Source Type: research

Rate and Risk Factors of Recurrent 30-Day Readmissions following Hospitalization for Ischemic Stroke (S47.003)
CONCLUSIONS: Patients with 30-day readmissions after index hospitalization for ischemic stroke remain at further risk for recurrent 30-day readmissions. Characterization of magnitude and risk factors of recurrent 30-day readmissions may provide framework for reducing such preventable readmissions.Disclosure: Dr. Moradiya has nothing to disclose. Dr. Murthy has nothing to disclose. Dr. Modi has nothing to disclose. Dr. Naval has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Moradiya, Y., Murthy, S., Modi, S., Naval, N. Tags: Cerebrovascular Disease and Interventional Neurology Source Type: research

Early improvement after IV tPA at the largest safety-net hospital in New England: the Boston Medical Center experience (P6.232)
CONCLUSIONS: Neurologic improvement within 24 hours was seen in half of our cohort. Patients who improved benefited despite high baseline NIHSS scores and multiple comorbidities. Interestingly time to needle onset was not a significant predictor for early improvement. Further efforts to include underserved populations in clinical trials should be undertaken to clarify key predictors of early improvement after tPA infusion in this population.Disclosure: Dr. Tawakul has nothing to disclose. Dr. Ge has nothing to disclose. Dr. Lau has nothing to disclose. Dr. Nguyen has nothing to disclose. Dr. Romero has nothing to disclose....
Source: Neurology - April 8, 2015 Category: Neurology Authors: Tawakul, A., Ge, G., Lau, H., Nguyen, T., Romero, J., Babikian, V., Kase, C., Masoud, H. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Thrombolysis Source Type: research